Ipamorelin: A Second Route to the Same Pituitary Cell

The short version

Ipamorelin is a small, five-amino-acid synthetic peptide (a pentapeptide) that activates the ghrelin receptor — the same receptor the "hunger hormone" ghrelin normally binds — on the pituitary gland's growth-hormone-producing cells. That triggers a pulse of growth hormone (GH) release. Its defining feature, established in the earliest pharmacology studies, is selectivity: unlike older GH-releasing peptides, it does this without meaningfully raising cortisol or prolactin, even at high doses.

It has never been approved as a drug for any use and is sold strictly as a research chemical. Like sermorelin and CJC-1295, ipamorelin is one of the most consistently reported sleep-improvement compounds in research-use communities, though — unlike sermorelin — the human clinical trial record for ipamorelin is thin, and its single published Phase 2 human trial did not meet its primary goal.

What it is

Ipamorelin's sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2 — alpha-aminoisobutyric acid at position 1, with D-2-naphthylalanine and D-phenylalanine substitutions that confer resistance to protease breakdown. It was derived from GHRP-1 by removing a central dipeptide, and it is a selective agonist at the ghrelin/growth hormone secretagogue receptor, GHS-R1a.

Ipamorelin is not an approved bulk drug substance for compounding. In 2024, the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk-substances list after its nominator withdrew, and it was reviewed at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting — a materially tighter regulatory position than sermorelin's.

How it works

Ipamorelin selectively activates GHS-R1a on pituitary somatotrophs, triggering a GH pulse through a mechanism distinct from and complementary to GHRH signaling — which is the pharmacological basis for pairing it with a GHRH analog such as CJC-1295. Unlike earlier growth-hormone-releasing peptides (GHRP-6, GHRP-2), ipamorelin does not meaningfully raise ACTH, cortisol, or prolactin even at doses far above the amount needed to release GH, which is its signature feature relative to the rest of the GHRP class.

What the research shows

The most recent published in-vivo ipamorelin study, a 2024 ferret model, gave intraperitoneal ipamorelin at 1 to 3 mg/kg and found it inhibited cisplatin-induced body-weight loss by roughly 24% during the delayed phase (48 to 72 hours) — but it had no anti-emetic effect on either acute or delayed chemotherapy-induced nausea ^[8].

Ipamorelin's human evidence base is narrow. The only published Phase 2 randomized controlled trial (114 adults undergoing bowel resection, given 0.03 mg/kg intravenously twice daily for up to 7 days) missed its primary endpoint: median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo (P=0.15). Treatment-emergent adverse events occurred in 87.5% of the ipamorelin group versus 94.8% of placebo, with no ipamorelin-specific safety signal in that short perioperative window ^[10]. Separately, population pharmacokinetic modeling in eight healthy male volunteers per dose level found dose-proportional kinetics with a terminal half-life of about 2 hours and a GH response peaking roughly 40 minutes after dosing as a single discrete pulse ^[11].

In adult female rats, 15 days of subcutaneous ipamorelin at 18, 90, and 450 micrograms/day dose-dependently increased longitudinal bone growth rate from 42 micrometers/day at baseline to 44, 50, and 52 micrometers/day respectively, with no measurable change in total IGF-1, IGF-binding proteins, or bone turnover markers ^[12].

A separate 28-day safety-pharmacology study of a different ghrelin-receptor agonist (GSK894281, not ipamorelin itself) found dose-dependent myocardial degeneration and necrosis in rats, detectable by histopathology and electron microscopy ^[9] — a class-level cardiovascular signal, not an ipamorelin-specific finding, but the reason chronic systemic dosing of any GHS-R1a agonist warrants safety scrutiny.

Reported effects, cautions & safety

The following community-reported effects are anecdotal, not clinical evidence, and no dose is implied by any of them.

Deeper, more restorative sleep is consistently the most-cited benefit in research-use community reports, with users describing falling asleep faster and waking more rested, often within one to two weeks of a pre-bed protocol; vivid dreams in the early weeks are also frequently mentioned. Faster physical recovery and reduced post-training soreness, and a gradual, subtle shift toward a leaner body composition over five to twelve weeks, are also frequently to occasionally reported.

On the adverse side, facial flushing and a brief head-rush shortly after injection — often compared to a niacin flush — is a widely noted, frequently reported reaction. Occasionally reported effects include tingling or numbness in the hands and feet, mild water retention, increased hunger (a predictable consequence of acting on the ghrelin receptor), and transient dizziness or a "spacey" feeling after dosing. Injection-site irritation is common but generally mild. Some community accounts describe a diminishing subjective response after three to four months of continuous use, echoing the standard on/off cycling rationale discussed in peptide forums.

The cited safety literature is largely mechanistic rather than ipamorelin-specific, because the controlled human dataset is so narrow: the class-level cardiotoxicity signal from a related GHS-R1a agonist ^[9], the fact that the only Phase 2 human trial did not demonstrate efficacy in its short perioperative window ^[10], and the absence of any long-term human safety data beyond that single trial and the acute-dosing pharmacokinetic study ^[11]. Ghrelin-receptor agonism is also mechanistically linked to appetite stimulation and, in preclinical models, to direct insulin release from pancreatic tissue — reasons the literature flags caution for people managing diabetes, insulin resistance, or weight. Research-grade ipamorelin from unregulated suppliers carries no pharmaceutical quality assurance, and ipamorelin is prohibited in sport under the WADA S2 category at all times.

Where it fits in the Growth Hormone Axis

Ipamorelin is the ghrelin-receptor arm of this desk — mechanistically distinct from sermorelin and CJC-1295, both of which work through the GHRH receptor. That separate pathway is the pharmacological basis for the CJC-1295/ipamorelin combination, which pairs ipamorelin's ghrelin-receptor pulse with a GHRH-receptor signal on the same somatotroph. See the comparison page for how all four line up.